Acute	B:C4289946
Ph-	I:C4289946
negative	I:C4289946
lymphoblastic	I:C4289946
leukemias	I:C4289946
in	O
adults	O
:	O
Risk	O
factors	I:C0035648
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

Acute	O
Ph-	I:C4289946
negative	I:C4289946
lymphoblastic	I:C4289946
leukemias	I:C4289946
in	O
adults	O
:	O
Risk	B:C0035648
factors	I:C0035648
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

Acute	O
Ph-	I:C4289946
negative	I:C4289946
lymphoblastic	I:C4289946
leukemias	I:C4289946
in	O
adults	O
:	O
Risk	O
factors	I:C0035648
in	O
the	O
use	O
of	O
the	O
ALL	B:C2348563
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	B:C0035648
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	B:C0035648
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	B:C0079611
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	B:C0023518
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	B:C0022917
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	B:C0022917
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	B:C0243102
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	B:C0544452
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	B:C0008625
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

to	O
analyze	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
(	O
risk	O
factors	I:C0035648
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	O
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	I:C0008625
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
in	O
the	O
use	O
of	O
the	O
ALL	B:C2348563
-	I:C2348563
2009	I:C2348563
protocol	I:C2348563
.	O

The	O
protocol	B:C2348563
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	I:C0033011
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	I:C4289946
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	B:C0043210
(	O
including	O
13	O
pregnant	O
women	I:C0033011
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	I:C4289946
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	B:C0033011
women	I:C0033011
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	I:C4289946
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	I:C0033011
)	O
and	O
161	O
men	B:C0025266
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	I:C4289946
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	I:C0033011
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	B:C4289946
ALL	I:C4289946
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	B:C0279593
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	B:C0279593
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	B:C0279593
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	B:C0279592
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	B:C0040113
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	O
-	I:C0279593
cell	I:C0279593
ALL	I:C0279593
(	O
early	O
pre-B	O
ALL	I:C0279593
(	O
n=51	O
)	O
;	O
common	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	I:C0279593
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	O
-	I:C0279592
cell	I:C0279592
ALL	I:C0279592
(	O
early	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=56	O
)	O
;	O
thymic	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
(	O
n=10	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	B:C0022877
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	B:C0449381
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	B:C0023518
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	B:C0279593
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	B:C0279593
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	B:C0022917
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	B:C0243102
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	B:C0150312
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	B:C0040715
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	B:C0279593
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	O
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
;	O
lactate	O
dehydrogenase	I:C0022917
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t(	I:C0040715
4;11	I:C0040715
)	I:C0040715
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

Thirty	O
-	O
five	O
patients	O
with	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
underwent	O
autologous	O
bone	I:C0194037
marrow	I:C0194037
transplantation	I:C0194037
(	O
bone	O
marrow	I:C0005961
transplantation	I:C0005961
)	O
.	O

Thirty	O
-	O
five	O
patients	O
with	O
T	O
-	I:C0279592
ALL	I:C0279592
underwent	O
autologous	B:C0194037
bone	I:C0194037
marrow	I:C0194037
transplantation	I:C0194037
(	O
bone	O
marrow	I:C0005961
transplantation	I:C0005961
)	O
.	O

Thirty	O
-	O
five	O
patients	O
with	O
T	O
-	I:C0279592
ALL	I:C0279592
underwent	O
autologous	O
bone	I:C0194037
marrow	I:C0194037
transplantation	I:C0194037
(	O
bone	B:C0005961
marrow	I:C0005961
transplantation	I:C0005961
)	O
.	O

Allogeneic	B:C0149615
BMT	I:C0149615
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	O
phase	I:C4049995
.	O

Allogeneic	O
BMT	I:C0149615
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	B:C4049995
phase	I:C4049995
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	B:C0220825
was	O
59	O
%	O
;	O
relapse	O
-	I:C0679867
free	I:C0679867
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
and	O
in	O
those	O
with	O
T	O
-	I:C0279592
ALL	I:C0279592
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	O
was	O
59	O
%	O
;	O
relapse	B:C0679867
-	I:C0679867
free	I:C0679867
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
and	O
in	O
those	O
with	O
T	O
-	I:C0279592
ALL	I:C0279592
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	O
was	O
59	O
%	O
;	O
relapse	O
-	I:C0679867
free	I:C0679867
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	B:C0279593
-	I:C0279593
ALL	I:C0279593
and	O
in	O
those	O
with	O
T	O
-	I:C0279592
ALL	I:C0279592
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	O
was	O
59	O
%	O
;	O
relapse	O
-	I:C0679867
free	I:C0679867
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	O
-	I:C0279593
ALL	I:C0279593
and	O
in	O
those	O
with	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
risk	B:C0035648
factors	I:C0035648
demonstrated	O
that	O
the	O
latter	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
p=0.013	O
)	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
demonstrated	O
that	O
the	O
latter	O
for	O
T	B:C0279592
-	I:C0279592
ALL	I:C0279592
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B	O
-	I:C0279593
ALL	I:C0279593
(	O
p=0.013	O
)	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
risk	O
factors	I:C0035648
demonstrated	O
that	O
the	O
latter	O
for	O
T	O
-	I:C0279592
ALL	I:C0279592
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B	B:C0279593
-	I:C0279593
ALL	I:C0279593
(	O
p=0.013	O
)	O
.	O

A	O
lower	O
chemotherapeutic	B:C0729502
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B:C0149615
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	B:C0087111
results	O
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	B:C0456984
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B:C0010858
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	B:C0010858
loading	O
dose	O
.	O

The	O
results	B:C0456984
of	O
the	O
Russian	O
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
.	O

The	O
results	O
of	O
the	O
Russian	B:C0035970
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
.	O

The	O
results	O
of	O
the	O
Russian	O
investigation	B:C0220825
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
.	O

The	O
results	O
of	O
the	O
Russian	O
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B:C0149615
BMTs	I:C0149615
in	O
adult	O
patients	O
with	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
.	O

The	O
results	O
of	O
the	O
Russian	O
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	O
BMTs	I:C0149615
in	O
adult	O
patients	O
with	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
.	O

